Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-48278-1
Abstract: Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity. However, DOAC treatment carries the risk of anticoagulant-associated… read more here.
Keywords: engineering evaluation; associated bleeding; fxa; evaluation fxa ... See more keywords